Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline-Reference-Cited by-同舟云学术

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Published:2022-09-13 Issue:10 Volume:31 Page:1027-1052
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Tamargo Juan¹,Tamargo María²,Caballero Ricardo¹

Affiliation:

1. Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain

2. Department of Cardiology, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain

Funder

Institute of Health Carlos III

Ministerio de Ciencia e Innovación

Comunidad de Madrid

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2113374

Reference193 articles.

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

2. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

3. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy

4. Clinical Course and Management of Hypertrophic Cardiomyopathy

5. Hypertrophic Cardiomyopathy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022;European Heart Journal - Cardiovascular Pharmacotherapy;2023-05-11

2. Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential;Expert Opinion on Investigational Drugs;2023-01-02